Search Results - Michael Meldgaard

  • Showing 1 - 3 results of 3
Refine Results
  1. 1

    No association between loss-of-function mutations in filaggrin and diabetes, cardiovascular disease, and all-cause mortality. by Lise Lotte N Husemoen, Tea Skaaby, Torben Jørgensen, Jacob P Thyssen, Michael Meldgaard, Pal B Szecsi, Steen Stender, Jeanne Duus Johansen, Allan Linneberg

    Published in PLoS ONE (2013-01-01)
    Get full text
    Article


  2. 2

    A possible association between a dysfunctional skin barrier (filaggrin null-mutation status) and diabetes: a cross-sectional study by Allan Linneberg, Torben Hansen, Jacob P Thyssen, Steen Stender, Oluf Pedersen, Berit C Carlsen, Jeanne D Johansen, Kåre Engkilde, Flemming Pociot, Michael Meldgaard, Pal B Szecsi, Torkil Menné

    Published in BMJ Open (2011-09-01)
    Get full text
    Article


  3. 3

    Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies by Amy Easton, Marianne L. Jensen, Congwei Wang, Peter H. Hagedorn, Yuwen Li, Michael Weed, Jere E. Meredith, Valerie Guss, Kelli Jones, Martin Gill, Carol Krause, Jeffrey M. Brown, Lisa Hunihan, Joanne Natale, Alda Fernandes, Yifeng Lu, Joe Polino, Mark Bookbinder, Greg Cadelina, Yulia Benitex, Ramola Sane, John Morrison, Dieter Drexler, Stephen E. Mercer, Charlotte Bon, Nikhil J. Pandya, Ravi Jagasia, Tai-Hsien Ou Yang, Tania Distler, Fiona Grüninger, Michael Meldgaard, Marco Terrigno, John E. Macor, Charles F. Albright, James Loy, Anja M. Hoeg, Richard E. Olson, Angela M. Cacace

    Published in Molecular Therapy: Nucleic Acids (2022-09-01)
    Get full text
    Article


Search Tools: